HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nestle Pairs Nutrition Science Business With Pharma Firm Making Peanut Allergy Treatment

Executive Summary

Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.

You may also be interested in...



US HBW Business News: OTC Migraine Treatment Device Cleared, Nestle Closes Aimmune Deal, More

Cefaly touts first OTC dual-Purpose eTNS migraine device available in US; Nestle Health Science closes on its acquisition of Aimmune Therapeutics; Elderberry supplement marketer Matherson Organics complies with NAD recommendations rather than face FTC scrutiny; and nutrition product firm Vidafuel closes on $1.6m financing round.

Nestle Acquires IM HealthScience, Expands Medical Food Lineup In Latest US Consumer Move

Nestle Health Science acquires IM HealthScience, marketer of medical foods IBgard and FDgard as well as prebiotic and sleep aid supplements. The deal is second recent US consumer health addition for the firm after it said 2020 would be “‘more vigorous” year for acquisitions despite the COVID-19 pandemic.

Doubts Over DBV's Future As US FDA Rejects Peanut Allergy Patch

The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel